Published OnlineFirst March 9, 2010; DOI:[removed].CAN[removed]Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic Chandini M. Thirukkumaran, Michael J. Nodwell, Kensuke

First Page		Document Content
Date: 2013-12-24 04:11:08 Oncology Cell lines Reolysin Oncolytic virus Oncolytics Biotech Prostate cancer Ras subfamily Reoviridae Management of cancer Biology Medicine Viruses		Published OnlineFirst March 9, 2010; DOI:[removed].CAN[removed]Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic Chandini M. Thirukkumaran, Michael J. Nodwell, Kensuke Add to Reading List Source URL: www.oncolyticsbiotech.com Download Document from Source Website File Size: 735,00 KB Share Document on Facebook

	Final Results of a Phase II Multicenter Trial of HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab Combination Treatment in Patients with Stage IIIB-IV Unresectable or Metastatic Melanoma Abstract #1664 DocID: 1v2ur - View Document
	Tumor response from Phase II study of combination treatment of intratumoral HF10, a replication - competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melano DocID: 1uTz9 - View Document
	When Patients Win, We All Win™ Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation DocID: 1rgN5 - View Document
	Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile. Photo courtesy of Dina Potter. Sunny Tree. 48" × 60". DocID: 1rePY - View Document
	OVC Crestword copy black read DocID: 1qyO0 - View Document